一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括BL-B01D1；Osimertinib，当前状态为招募中。登记地点显示中国济南有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BL-B01D1；Osimertinib · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital of Shandong First Medical University · 济南
公开的入选条件
- 1. Voluntarily sign the informed consent form and comply with the protocol requirements;
- 2. Age ≥ 18 years and ≤ 75 years, regardless of gender;
- 3. Expected survival time ≥ 3 months;
- 4. Unresectable Stage III non-small cell lung cancer;
- 5. Detection of one of the EGFR-sensitive mutation types in tumor tissue;
- 6. Agree to provide archived primary tumor tissue specimens or fresh tissue samples within 1 year;
- 7. In platinum-based radical chemoradiotherapy, the platinum-containing chemotherapy regimen must include one of the specified drugs in addition to the platinum agent;
- 8. In platinum-based radical chemoradiotherapy, patients must have received a total radiation dose of 60 Gy ± 10% before randomization;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07640789；登记信息更新于 2026-09-10。